Allogeneic hematopoietic cell transplant (HCT) in patients (pts) ≥ 60 years of age with first relapsed or refractory acute myeloid leukemia (R/R AML) after treatment with vosaroxin plus cytarabine (vos/cyt) vs placebo plus cytarabine (pla/cyt): Results from VALOR.
Year: 2015
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Gary J. Schiller, Ellen K. Ritchie, Hamid Sayar, Jeffrey E. Lancet, Michael D. Craig, Norbert Vey, Stephen Anthony Strickland, Harry Paul Erba, Arnaud Pigneux, Heinz-August Horst, Christian Recher, Virginia M. Klimek, Olatoyosi Odenike, Adam R. Craig, Renee Ward, Jennifer Smith, Hagop M. Kantarjian, Robert K. Stuart, Farhad Ravandi, VALOR Investigators Group
Institutions: University of California, Los Angeles, Cornell University, Weill Cornell Medicine, Indiana University Indianapolis, University of South Florida, Moffitt Cancer Center, West Virginia University, Institut Paoli-Calmettes, Vanderbilt University, Vanderbilt-Ingram Cancer Center, University of Alabama at Birmingham, Centre Hospitalier Universitaire de Bordeaux, University Hospital Schleswig-Holstein, Centre Hospitalier Universitaire de Toulouse, Hôpital Purpan, Memorial Sloan Kettering Cancer Center, University of Chicago, Sunesis (United States), The University of Texas MD Anderson Cancer Center, Medical University of South Carolina
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2602642116